Media Center Found (716)
Array ( [cache_time] => 0 [counts_time] => 0 [query_time] => [total_time] => 0 )
December 26, 2008

Yissum launches a $1 million program for the development of outstanding cleantech inventions by scientists at the Hebrew University of Jerusalem 

More
December 25, 2008

Yissum cordially invites you to the launch of the Yissum Cleantech Fund Featuring keynote speaker: Mr. Yehuda Bronicki, Chairman and CTO of Ormat, and highlighting two of the projects supported by the fund of Prof. Yoel Sasson and of Prof. Uri...

More
December 17, 2008

Initial cleantech inventions chosen include technologies aimed at reducing polluting effects of fossil fuels and creating alternative clean energy sources

More
December 17, 2008

Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, is launching a 1 million U.S. dollar programme to support the development of outstanding cleantech inventions by scientists at the Hebrew University of Jerusalem.

More
December 16, 2008

Teva will finance Jexys' R&D program for the development of a high throughput drug discovery platform and in return will receive a minority equity interest in Jexys Pharmaceuticals. 

More
December 15, 2008

Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, announces today that its subsidiary Jexys Pharmaceuticals has signed a strategic research and development agreement with Teva Pharmaceuticals Industries Ltd. Under the...

More
December 11, 2008

Inventions of Professors Citri, Mitrani and Baniyash receive fundings from Yissum's new Baby Seed Fund 

More
December 11, 2008

Inventions of Professors Citri, Mitrani and Baniyash receive fundings from Yissum's new Baby Seed Fund 

More
December 10, 2008

Yissum Spin-off Mobileye, a developer of crash-detection technology, is doing just fine despite the dark cloud over the automotive industry

More
December 1, 2008

"We are experiencing a historic moment in time that offers the possibility to become key players in a new evolving industry." Says Dan Vilensky, Co-Chairman of the upcoming NanoIsrael 2009 Conference, that shall take place in Jerusalem on March...

More
November 28, 2008

The Championship of ideas - Il Sole 24 Ore Milano

More
November 27, 2008

How do you transform research taking place in the ivory towers of academic institutes into viable products in the free market? 

More
November 20, 2008

Ziv Shomroni, Yissum’s VP Natural Sciences and Prof. Yoel Sasson of the Institute of Chemistry presented selected technologies of researchers of the Hebrew University at the Singapore Techlicensing Faire: Energy & Environment in September.

More
November 16, 2008

'The Scientist' ranks Israeli academic institutions in first, second places in its annual search 'the best places to work in academia' outside the US

More
November 13, 2008

Yissum, the technology transfer company of the Hebrew University of Jerusalem, has granted a worldwide exclusive license to BioLineRx to develop and commercialize BL-5040, a new antihormone for the treatment of inflammatory diseases.

More
November 12, 2008

Yissum the Technology Transfer Company of the Hebrew University of Jerusalem, and BioLineRx , a clinical stage drug development company, today announced that they have signed a worldwide exclusive license agreement for BioLineRx to develop and...

More
November 9, 2008

Prof. Arie Belldegrun, Yissum's guest speaker at Biomed 2008, is convinced that the 21st century will focus on Biotech and calls upon all Israeli scientists to join hands in forming a flourishing Israeli Biotech industry.   

More
October 27, 2008

PharmAthene Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a U.S. Phase I clinical trial evaluating Protexia(R) for safety and...

More
October 8, 2008

Prof. Daphne Atlas was chosen for her breakthrough research for treatment of  neurodegenerative diseases. Her invention of an orally-available small molecule was licensed by Yissum to Eucalyptus Ltd. 

More